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ABSTRACT 
Somatostatin (somatotropin release inhibitory factor; SRIF) is a peptide-signaling 
molecule that activates a family of heterotrimeric guanine nucleotide binding protein (G­ 
protein) coupled receptors (sst.-sst-). SRIF receptors control essential intracellular 
signaling events and, by reducing cyclic nucleotide levels, ion concentrations and protein 
phosphorylation, ultimately controlling cell proliferation and secretion. In the current 
study, we investigated the intracellular phosphatase activity present in the AtT-20 cell, as 
well as whether these enzymes were under direct SRIF receptor control. AtT-20 cells 
retain many of the properties of anterior pituitary corticotrophs, yet are an established cell 
line that expresses at least two SRIF receptor subtypes (sst, and sst.). Both SRIF receptor 
subtypes potently suppress hormonally induced adrenocorticotropic hormone (ACTH) 
secretion from AtT-20 cells. Since intracellular protein kinase activation plays a crucial 
role in ACTH release from AtT-20 cells, identifying the corresponding protein 
phosphatases will provide valuable information on corticotroph function. The novel 
fluorescent phosphatase substrate, 6,8-difluoro-4-methylumbelliferyl phosphate (DiF­ 
MUP) was employed to identify soluble or membrane-associated phosphatase activities. 
Treatment with a selective tyrosine phosphatase inhibitor (sodium vanadate; Na3 V04) 
attenuated DiF-MUP phosphatase activity by 75%, suggesting that the dominant activity 
detected in AtT-20 cells is a tyrosine phosphatase. Na3V04 inhibition was potent as 
concentration response studies demonstrated an inhibitory concentration for 50% activity 
(ICso) of 90 nM. A serine/threonine phosphatase inhibitor failed todecrease phosphatase 
activity, indicating that the dominant phosphatase activity present is due to protein 
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tyrosine phosphatases. Immunoprecipitation studies, in conjunction with sodium dodecyl 
sulfate polyacrylamide electrophoresis (SDS-P AGE) and immunoblotting identified two 
intracellular phosphotyrosine phosphatases: Src homology phosphatase- I (SHP-1) and 
Src homology phosphotyrosine phosphatase-2 (SHP-2). Immunoblotting with phospho­ 
specific antisera confirmed the presence of SHP-1 and SHP-2, while also demonstrating 
that neither enzyme appears to be under SRIF control in AtT-20 cells. Together, these 
results show that AtT-20 murine corticotrophs contain sodium vanadate sensitive, soluble 
tyrosine phosphatase activity that is independent of SRIF control. 
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INTRODUCTION 
Protein phosphatases are ubiquitous enzymes responsible for the 
dephosphorylation of intracellular proteins. These enzymes antagonize the effects of 
protein kinases, which phosphorylate proteins predominately on serine, threonine and 
tyrosine residues. Three major categories of protein phosphatases have been identified 
based on their preference for dephosphorylating the amino acid residues tyrosine, 
serine/threonine, or both tyrosine and threonine. 
Protein tyrosine phosphatases (PTPs) are categorized into groups that either 
contain or lack a transmembrane domain, and are further subdivided into 17 groups 
(Andersen et al, 2001). PTPs, such as SHP-2 (SH2 containing protein tyrosine 
phosphatase 2), contain a src homology 2 (SH2) domain composed of approximately 100 
amino acids, including a tyrosine residue that undergoes phosphorylation, followed by 
Glu-Glu-Ile, leading to specificity in signaling control. PTPs regulate phosphorylated 
tyrosine residues, thereby controlling cell growth and differentiation (reviewed in Tonks 
and Neel, 1996). A second type of PTP, SHP-1, is responsible for dephosphorylating 
signaling molecules such as p27 (Kip 1 ), leading to cell cycle arrest (Pages et al, 1999). 
Serine/threonine phosphatases regulate diverse cellular mechanisms including glycogen 
metabolism, DNA replication, and exocytosis (Sim et al, 2003). Threonine/tyrosine 
phosphatases, known as dual specificity MAPK phosphatases (DS-MKPs) regulate the 
mitogen-activated protein kinases (MAPKs), which are critical protein kinases that 
regulate diverse physiological events, such as long-term potentiation, and inflammation 
(Wera and Hemmings, 1995; Farooq and Zhou, 2004). Dual-specificity phosphatases 
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(DSPs) aid in controlling the cell cycle by interacting with both MAPKs and stress 
activated kinases (Keyse, 1999). 
Somatostatin (somatotropin release inhibitory factor; SRIF) was originally 
identified in the central nervous system as a hypothalamic inhibitor of growth hormone 
release (Brazeau et al, 1973). SRIF exists in two distinct forms, SRIF-14 and SRIF-28, 
both originating from the SRIF-prepropeptide. SRIF is distributed throughout the entire 
human body, with SRIF-28 predominately localized in the gastrointestinal tract and 
SRIF-14 localized to the nervous system (Reisine, 1995). SRIF peptides regulate a 
spectrum of endocrine effects, including thyroid-stimulating hormone (Singh et al, 2000), 
modulating gastric acid secretion (Larsson et al, 1979), and inhibiting pancreatic insulin 
and glucagon secretion (Strowski et al, 2000). 
SRIF carries out its actions by interacting with a group of five highly homologous 
SRIF receptors subtypes (sst, - sste), including the sst, receptor splice-variants (sst2A and 
sst29). This receptor family exists in an overlapping expression pattern in many tissue 
types throughout the body (Reisine, 1995; Vanetti et al, 1992). The SRIF membrane 
receptors are seven transmembrane spanning proteins that couple to intracellular 
heterotrimeric guanine nucleotide-regulated proteins (G proteins) (Reisine, 1995). 
Through G protein activation and appropriate effector stimulation, SRIF receptors 
regulate cyclic nucleotide levels, membrane ion conductances, and cellular protein 
phosphorylation levels (Florio and Schettini, 1996). 
AtT-20 cells are a transformed mouse corticotroph cell line which constitutively 
express a number of neuronal features, including cytoplasmic processes that resemble 
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neuronal growth cones, neurofilament polypeptides, as well as neuron-specific 
phosphoprotein synapsin 1 (Tooze et al, 1989). In addition, and of importance in the 
current study, the AtT-20 cells endogenously co-express the sst2A, zs, and sst-, but not sst., 
3, 4 SRIF receptor subtypes (Strowski et al, 2002; Cervia et al, 2003). AtT-20 cells retain 
the important property of primary corticotrophs, such as the hormonally regulated 
secretion of adrenocorticotropic hormone (ACTH) (Gumbiner and Kelly, 1 98 1 ;  reviewed 
in Antoni, 2000). Both corticotropin-releasing factor (CRF) and leukemia inhibitory 
factor (LIF) serve as potent ACTH secretagogues in corticotrophs and AtT-20 cells, 
making the AtT-20 cell an attractive model for studying ACTH stimulus-secretion 
coupling. (Vale et al, 1983; Auernhammer, 1998). SRIF treatment inhibits ACTH 
secretion by reducing intracellular 3 ', 5' cyclic adenosine monophosphate ( cAMP) levels 
and suppressing calcium ion influx (Heisler et al, 1982; Richardson, 1983). 
Mitogen-activated protein kinases (MAPKs) and signal transducers and activators 
of transcription (ST A Ts) have also been implicated in ACTH secretion by AtT-20 cells. 
Phosphotyrosine phosphatases may dephosphorylate the activated kinases, leading to a 
halt in ACTH release. SRIF's ability to inhibit these intracellular signaling pathways 
may be due to the recruitment of protein phosphatases, capable of dephosphorylating the 
activated kinases. In murine NIH 3T3 cells, SRIF regulates dephosphorylation of the 
tyrosine residue of Raf-1, a mitogen-activated kinase kinase kinase (MAPKKK), by 
stimulating protein tyrosine phosphatase activity (Reardon et al, 1996). SRIF's 
inhibitory effects on AtT-20 cellular function, including the reduction of both cAMP and 
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phosphorylated MAPK levels, led us to investigate and identify the possible protein 
phosphatase activity within this cell line. 
In the current study we have characterized the endogenous protein phosphatase 
activity of the AtT-20 murine corticotroph. Using a fluorescent enzymatic (6,8-difluoro- 
4-methylumberiferyll phosphate; DiF-MUP) assay in conjunction with enzymatic 
phosphatase inhibitors, immunoprecipitation and immunoblotting we have established the 
presence of soluble phosphotyrosine phosphatase activity. Our results suggest the 
presence of a soluble tyrosine phosphatase activity that is independent of SRIF 
regulation. 
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MATERIALS AND METHODS 
Cell culture 
The AtT-20 cell line used in this study was a gift from Dr. Terry Reisine (Los 
Angeles, CA). Cell culture dishes and flasks were purchased from Coming (Coming, 
NY). Cell culture growth medium and supplements were purchased from Invitrogen 
(Carlsbad, CA). AtT-20 cells were cultured in Dulbecco's modified Eagle's medium, 
DMEM, (with GlutaMAXrn, high glucose, l lOmg/L sodium pyruvate and pyridoxine­ 
HCL, Invitrogen, Carlsbad, CA) containing 100 U ml"1 of penicillin, lOOµg ml" 
streptomycin, and 10% (v/v) fetal calf serum. Cultures were maintained in 5% C02 at 
37°C. Cell monolayers were grown in T-75cm2 flasks and passaged when 75% 
confluence was reached. Cell suspensions were transferred to a new T- 75cm2 flask at a 
1 :  10 dilution. Cells were given 48 hours to recover prior to experimentation. 
Tyrosine phosphatase assay 
AtT-20 cultures were incubated in the presence or absence of lOOnM SRIF-14 
(Peninsula Labs, Belmont, CA) for 30 min. Cell cultures were washed in PBS and then 
lysed in a 50mM HEPES buffer containing 0.5% Triton X-100, 10% glycerol 
(GibcoBRL), 2.5µM pepstatin A, 12.5µM leupeptin, 12.5µM aprotinin, 12.5µM 
bacitracin and 200nM polymethylsulfonyl fluoride. Lysates were then centrifuged at 
13,500 x g for 1 5  min at 6°C and the supernatant retained. 
Protein phosphatase assays were performed in a clear bottom 96 well plate 
(Coming, Coming, NY). AtT-20 cell lysate was incubated with varying concentrations 
of the fluorescent phosphatase substrate, 6,8-difluoro-4-methylumbelliferyll phosphate 
1 1  
(DiF-MUP; Gee et al, 1999; Molecular Probes, Eugene, OR) up to 30 min at 37°C with 
intermittent mixing in a CytoFluor Series 4000 fluorescent plate reader (Applied 
Biosystems, CA), with 360nm excitation and 460nm emission filters. Parallel assays 
were conducted in the presence of lOµM Na3V04, an inhibitor of tyrosine phosphatase 
activity and a commercial 10 mM serine/threonine phosphatase inhibitor cocktail (Sigma, 
MO). The resulting data were analyzed with GraphPad Prism 4.0. 
Immunoprecipitation 
AtT-20 cells were cultured in T-75cm2 flasks with DMEM and then incubated for 
15  minutes with lOOnM SRIF-14. Cells were washed with 5 mL PBS (with MgCl and 
CaCl, Invitrogen, Carlsbad, CA) and lysed with 500 µL of 50mM HEPES buffer. 
Supernatants were obtained and incubated overnight with phospho-SHP-1 or SHP-2 
antibody (Cell Signaling, MA). Protein G agarose beads ( 450 mg/ml., Sigma, St. Louis, 
MO) were added and pellets were obtained and washed with 50 µL of 50mM HEPES 
buffer and resuspended in 1 X NuP AGE LDS sample buffer. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting 
AtT-20 cells were cultured in 12-well plates with medium (DMEM) for 48 hand 
then incubated in the presence or absence of 1 OOnM SRIF-14 for 20 min at 3 re. AtT-20 
cells were then lysed using IX NuPAGE LDS sample buffer. Cell lysates were sonicated 
and heated to 70°C for 10  min, resolved on NuPAGE 10% Bis-Tris gels (Invitrogen Life 
Technologies, CA) electroblotted onto polyvinyldifluoride (PVJ?F) membranes and 
treated for 45 min in a blocking buffer containing 5% (w/v) of Carnation non-fat 
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dehydrated milk. Phospho-SHP-1 and SHP-2 were then immunodetected with a 1 :  1000 
dilution of anti phospho-SHP-1 and anti-SHP-2 antibodies, respectively. The PVDF 
membrane associated immunoreactivity were then washed and incubated for 1 hour in a 
1 :2000 dilution of a horseradish peroxidase-conjugated anti-rabbit secondary antibody 
and detected using ECL chemiluminescence (Amersham, NJ). The resulting 
autoradiograph was scanned and integrated pixel density was obtained using NIH Scion 
Imaging software. 
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RESULTS 
Tyrosine Phosphatase Activity in AtT-20 cell lysate 
To identify a possible role of SRIF-14 in controlling AtT-20 cellular phosphatase 
activity, experiments using increasing concentrations of the fluorescent substrate DiF- 
MUP were performed with AtT-20 cell lysates prepared from untreated and treated (100 
nM SRIF-14) cultured cells. DiF-MUP hydrolysis provides a fluorescent measure of 
protein phosphatase activity (Gee et al, 1999). Cleavage of the phosphate group results 
in the product 6,8-difluoro-4-methylumbelliferone, a fluorescent molecule capable of 
emitting high levels of fluorescence. 
O F 
I I  
HO-P-O 
I  
OH 
F 
Figure 1. Chemical structure of 6,8-difluoro-4-methylumbelliferryl phosphate (DiF­ 
MUP). Gee et al, 1999; Molecular Probes, Eugene, OR. 
A concentration-response relationship for DiF-MUP was established by 
incubating increasing concentrations ofDiF-MUP with a soluble fraction from the AtT- 
20 cell lysate (Figure 2). Non-linear regression analysis of the fluorescence results 
revealed an approximate effective concentration for 50% activity (EC50) of 
approximately 50 µM. However, as shown in Figure 2, it should be noted that the lysate 
enzyme saturation could ·not be achieved, even at the highest D IF-MUP concentrations 
used in this study. In addition, the concentration-response curve indicates that no 
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significant difference exists between SRIF-14 treated and non-treated samples (Figure 2). 
Experiments performed with AtT-20 cell membranes prepared from cultured cells 
demonstrated similar results, indicating that SRIF-14 had no significant effect on 
membrane protein phosphatase activity ( data not shown). 
Tyrosine Phosphatase Activity in AtT-20 Cell Lysate 
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Figure 2. Tyrosine phosphatase activity in AtT-20 cell lysate. Cell monolayers were 
incubated in the presence or absence of 100 nM SRIF-14 for 15  min at 3 7°C. A soluble 
cell lysate was prepared by lysis of the AtT-20 cell monolayers, and fluorescent activity 
was assessed in a 96-well using a Cytofluor 4000 fluorescent plate reader (Applied 
Biosystems). Assays were conducted in triplicate and the data mean± SEM of twelve 
separate experiments are shown. 
AtT-20 lysate tyrosine phosphatase inhibition by sodium vanadate (Na3VOJ 
DiF-MUP provides a convenient and robust fluorescent measure of protein 
phosphatase activity, which when combined with an appropriate enzyme inhibitor, can 
help characterize and define the type of phosphatase activity being studied (Gee et al, 
1999). For example, phosphotyrosine phosphatases are exquisitely sensitive to the potent 
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tyrosine phosphatase inhibitor sodium vanadate, Na3 V04 (Swarup et al, 1982). 
V anadate-mediated enzyme inhibition serves as a readily available marker for 
establishing the amount of tyrosine phosphatase activity present in a heterogeneous cell 
lysate. To establish the level of tyrosine phosphatase activity in the AtT-20 cell lysates, 
approximately 50 µg of AtT-20 cell lysate was incubated for 15  min with 50 µM DiF- 
MUP in the presence or absence of 10  µM Na3 V04. DiF-MUP activity was reduced in 
AtT-20 cell lysate samples approximately 75% by Na3V04 (Figure 3; * p < 0.05 vehicle 
AtT-20 Lysate Tyrosine Phosphatase Inhibition ( 1 5  min incubation) 
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Figure 3. Sodium vanadate attenuates protein phosphatases activity in AtT-20 cell 
lysate. AtT-20 cell monolayers were prepared in cell lysis buffer and lysates were 
incubated 15 minutes with 50 µM DiF-MUP in the presence or absence of 10  µM 
Na3 V04. Fluorescence was measured using a Cytofluor 4000 plate reader and data were 
analyzed in GraphPad Prism 4.0. One way ANOVA followed by Dunn's non-parametric 
post hoc test,* p< 0.05 compared vehicle to Na3V04 treated AtT-20 cells. 
To determine the potency ofNa3V04 on tyrosine phosphatase activity, increasing 
concentrations of sodium vanadate were added to cell lysates. The DiF-MUP activity 
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found in the cell lysate exhibits a potent sensitivity to Na3 V04, as non-linear regression 
analysis of the DiF-MUP inhibition revealed a 50% inhibitory concentration (IC50) of 
approximately 90 nM (Figure 4). 
Na3 V04 Inhibition of Tyrosine Phosphatase Activity 
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Figure 4. Sodium vanadate inhibition of DiF-MUP activity in AtT-20 cell lysate. AtT-20 
cell lysates were prepared in the cell lysis buffer and incubated 15  minutes with 50µM 
DiF-MUP and Na3 V04 at concentrations ranging from 10·
9M to 104M. The IC50 value in 
control cell lysates was 90nM. 
AtT-20 cell lysate phosphatase inhibition with serine/threonine cocktail inhibitor 
To determine if DiF-MUP hydrolysis is also sensitive to serine/threonine 
phosphatase activity, AtT-20 cell lysates were co-incubated with 50 µM DiF-MUP and 
10 mM serine/threonine phosphatase cocktail inhibitor for 15  minutes. Statistical 
analysis of the inhibition data (using Dunn's non-parametric post-hoc test) shows no 
significant difference between the cocktail inhibitor treated and non-treated samples, 
indicating that serine/threonine phosphatases do not play a significant role in DiF-MUP 
hydrolysis under these experimental conditions (Figure 5). 
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AtT-20 lysate Phosphatase Assay with Cocktail lnibitor Treatment 
(15 min incubation) 
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Figure 5. Phosphatase inhibitor cocktail effect on DiF-MUP activity in AtT-20 cell 
lysate. AtT-20 cell lysates were prepared in the cell lysis buffer and incubated 1 5  
minutes with 50µM DiF-MUP and lOmM of the phosphatase inhibitor cocktail. 
Fluorescence was measured using a Cytofluor 4000 plate reader and data were analyzed 
in GraphPad Prism 4.0. One-way ANOVA, followed by Dunn's non-parametric post hoc 
test, shows no significant difference. 
Identification of SHP-2 and Phospho-SHPl in AtT-20 cells 
The tyrosine phosphatase SHP-2 has been implicated in SRIF actions in several 
cellular models. For example in S49 cells, the endogenously expressed sst2 receptor 
couples an increase in protein tyrosine phosphatase activity to a suppression of MAP 
kinase activity (Dent et al, 1997). SRIF-14 treated and non-treated AtT-20 cell 
monolayers were lysed with IX SDS and proteins were separated using gel 
electrophoresis. SHP-2 phosphatase (72 kDa) was detected using an anti-SHP-2 
polyclonal antibody. A paired student T-test was performed demonstrating that the 
SRIF-14 treated sample is not significantly different from the control sample. 
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Presence of SHP-2 in AtT-20 cells 
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Figure 6. Detection of SHP-2 in the AtT-20 cell. Parallel cultures of AtT-20 cells were 
incubated in the presence or absence of 100 nM SRIF-14 for 20 minutes. Cell lysates 
were separated by SDS-PAGE, electroblotted, and incubated with anti-SHP-2 antibody. 
Autoradiographs were quantified using NIH Scion image. The results represent the mean 
+SEM of three separate experiments. The paired student T-test shows no significant 
difference between the vehicle and SRIF-14 treated samples. The inset shows a 
representative autoradiograph. 
The SHP-1 phosphatase plays a role in regulating intracellular signaling events 
leading to cell cycle arrest and cell growth inhibition (Ferjoux et al, 2003). A polyclonal 
anti-Phospho-SHPl antibody identified the tyrosine phosphatase (140 kDa) in SDS- 
PAGE resolved and electroblotted AtT-20 cell lysates. SRIF-14 did not appear to control 
SHP-1 phosphorylation as no statistically significant difference was observed on the 
percent integrated density values obtained from the control and SRIF-14 treated samples. 
(p > 0.05; paired Student t-test) 
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Presence of Phospho-SHP1 in AtT-20 cells 
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Figure 7. Detection of Phospho-SHPl in AtT-20 cells. AtT-20 cell lysates were 
separated by SDS-PAGE, electroblotted and incubated with anti-Phosph-SHPl primary 
antibody. Images were quantified using NIH Scion Image. The results represent the 
mean +SEM of three separate experiments. The paired student T-test shows no 
significant difference between the vehicle and SRIF-14 treated samples. The inset shows 
a representative autoradiograph. 
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DISCUSSION 
SRIF regulates multiple intracellular signaling pathways such as intracellular ion 
concentrations, cyclic nucleotide levels and protein phosphorylation (Blake et al, 2004; 
Olias et al, 2004). Protein phosphorylation controlled by SRIF includes the activation of 
phosphoprotein phosphatases (Olias et al, 2004) that are responsible for regulating crucial 
cellular events, including cell growth and proliferation, differentiation, and cell cycle 
progression. 
SRIF receptor subtypes are well documented in the AtT-20 cell, controlling cyclic 
nucleotide metabolism (Strowski et al, 2002; Cervia et al, 2003) and hormonal secretion 
(Strowski et al, 2002). In the AtT-20 cell model, SRIF inhibits ACTH release via both 
cAMP independent and dependent mechanisms, suggesting that multiple intracellular 
events may be under SRIF control (Litvin et al, 1986, Reisine et al, 1988; Mcferran and 
Guild, 1996). However, whether SRIF events outside of intracellular ion concentrations 
or cyclic nucleotide metabolism are affected remains unknown. In the current study, we 
sought to establish and identify the protein phosphatase family of enzymes in the AtT-20 
cell, which may serve to inactivate the protein kinases responsible for ACTH secretion. 
Within the AtT-20 cell, we have identified at least two cytosolic protein tyrosine 
phosphatases, SHP-1 and SHP-2. We used the fluorescent substrate difluoro-4- 
methylumberiferyll phosphate (DiF-MUP) in combination with sodium vanadate to 
measure the relative fluorescence of PTPs upon SRIF-treatment, as a means of indirectly 
determining phosphatase activity. Our results demonstrate that basal phosphatase activity 
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was not affected by SRIF incubation, suggesting that within AtT-20 cells, PTPs, 
including SHP-1 and SHP-2, act independently of SRIF activation. 
Both SHP-1 and SHP-2 have been identified in previous studies, but this 
experiment provides the first indication of the presence of these protein tyrosine 
phosphatases within a corticotroph cell line, such as the AtT-20 cell. SHP-1 plays a 
largely inhibitory role within a cell, negatively regulating both cytokine and growth 
receptors, as well as intracellular signaling molecules such as Janus activating kinase 2 
(Jak2) (Tonks and Neel, 2001; Wu et al, 2000). In the AtT-20 cell, SHP-1 function may 
dephosphorylate both growth and cytokine receptors, the CRF- and LIF-receptors, 
respectively. The negative regulation of both G protein coupled receptors and an 
interleukin-6 cytokine receptor would prove important in the overall control of ACTH 
secretion. 
SHP-2 function in a cell demonstrates both negative and positive regulatory roles. 
SHP-2 activity involves inactivation and dephosphorylation of both JAK and STAT in rat 
brain microglial cells, but it functions as a positive regulator of receptor tyrosine kinase 
signaling (Kim et al, 2003; Keyse, 2000). Within the AtT-20 cell, SHP-2 may co­ 
regulate ACTH secretion with SHP-1 via a cytokine-induced pathway leading to the 
activation of JAK-STAT signaling proteins. In rat pancreatic cancer cells, both SHP-1 
and SHP-2 have been found to work in conjunction with one another by coupling to ssh 
(Ferjoux et al, 2003), indicating a potential mechanism for SRIF control of these PTPs. 
Our results indicate that within the AtT-20 cell, both SHP-1 and SHP-2 are independent 
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of SRIF function, suggesting that neither PTP is docked to the sst, receptor under basal 
conditions. 
AtT-20 cells endogenously express the SRIF receptor subtypes sst2 and sst5; 
however, sst, has been reported to be the dominant receptor subtype in the rodent 
pituitary corticotroph (Patel et al, 1996). Studies have shown that SHP-1 is constitutively 
associated with sst-, rather than sst-, and displays antiproliferative effects in CHO 
(Chinese hamster ovarian) cells when the stimulated ssh receptor activates the tyrosine 
phosphatase (Lopez et al, 1997). In contrast, CHO cells transfected with sst, do not 
recruit either protein tyrosine phosphates or serine/threonine phosphatase (Buscail et al, 
1995). Provided with this information, we can speculate that the AtT-20 cell responds to 
SRIF-14 via sst, rather than sst, to regulate the activity of PTPs. The expression profile 
of ssts2&5 in the AtT-20 may explain the inability of SRIF-14 to significantly increase 
PTP levels. A novel approach to clarify the SRIF receptor pharmacology may involve 
profiling ssh selective agonist-induced PTP expression. Delineating SRIF' s intracellular 
effects via different receptors could serve to answer the question of why multiple receptor 
subtypes are co-expressed in individual cells and tissues, a question that may have 
significant therapeutic implications for hormone secretion from SRIF sensitive tissues 
(Blake et al, 2004; van der Hoek et al, 2005). 
While SRIF has been shown to have no direct effect on basal tyrosine 
phosphatase activity in AtT-20 cells, SRIF's effects on stimulated AtT-20 cells has not 
been examined. Clearly, future experiment measuring SRIF's actions on tyrosine 
phosphatase activity in LIP-stimulated AtT-20 cells may demonstrate an increase in 
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activity. Leukemia inhibitory factor (LIF), has been shown to increase ACTH secretion 
in AtT-20 cells (Auernhammer et al, 1996) through the JAK-STAT intracellular signaling 
pathway. Studies have shown that endogenously expressed LIF receptors stimulate 
Janus-activated kinases (JAK), a family of tyrosine kinases located within the AtT-20 cell 
membrane. (Stahl et al, 1994). Following activation, signal transduction and activation 
of transcription (ST AT) proteins are phosphorylated on tyrosine residues and translocate 
to the nucleus to promote the expression of proopiomelanocortin (POMC), the precursor 
to ACTH. SRIF may recruit protein tyrosine phosphatases capable of dephosphorylating 
STA T3 on tyrosine residues, preventing nuclear localization and subsequent POMC gene 
expression. Recruitment of PTPs, such as SHP-1 and SHP-2, could occur by association 
with ssti, based on the ability these phosphatases to interact with the SRIF receptor 
subtype. 
The importance of delineating the regulatory mechanism of ACTH secretion from 
the murine corticotroph may provide a model relevant in understanding the aberrant 
secretory responses in Cushing's syndrome. Cushing's syndrome is a hormonal disorder 
caused by the hyperstimulation of the adrenal gland by ACTH, allowing dangerous levels 
of cortisol to be released. This can be caused by pituitary adenomas and impose 
detrimental effects on a patient, including high blood pressure, high blood glucose levels 
and obesity. Currently, research is being conducted on the SRIF pharmacological 
analogue, SOM230, and its ability to inhibit ACTH secretion from both human and 
mouse corticotroph adenomas (Hofland et al, 2005). Uncovering a potential role of 
protein tyrosine phosphatases in ACTH secretion could assist in understanding the 
24 
mechanism of SOM230 inhibition, solidifying its role as a potential therapeutic agent for 
Cushing's syndrome. 
25 
CONCLUSIONS 
In summary, the activation of protein kinases within the AtT-20 cell regulates the 
cellular processes involved in ACTH secretion. SRlF has been shown to inhibit the 
secretion of ACTH in AtT-20 cells by regulating cyclic nucleotide levels, ion 
conductance, and protein phosphorylation. While the protein kinases involved in AtT-20 
cellular mechanisms have been well characterized, protein phosphatases responsible for 
antagonizing protein kinase effects have yet to be determined. 
Our results demonstrate that AtT-20 cells contain a soluble protein phosphatase 
activity capable of hydrolyzing the fluorescent substrate DiF-MUP. This protein 
phosphatase activity is independent of SRIF control, but is exquisitely sensitive to 
sodium vanadate, a potent tyrosine phosphatase inhibitor. The sensitivity of the 
enzymatic activity to sodium vanadate indicates that protein tyrosine phosphatases are 
present within the AtT-20 cell. Further inspection of this activity led to the identification 
of the protein tyrosine phosphatases SHP-2 and SHP-1 within the murine corticotroph, 
however neither phosphatase was under the control of SRlF. 
AtT-20 cells endogenously co-express three SRJF receptors; sst2A, sst2B, and sst« 
Future studies, with receptor-selective agonists, should be used to delineate each 
receptor's influence on SRIF's effects on tyrosine phosphatase activity in AtT-20 cells. 
Further investigation of tyrosine phosphatase recruitment in AtT-20 cells stimulated by 
LIF should be performed in order to develop a possible regulatory mechanism of ACTH 
secretion. This information could lead to a better understanding of how ACTH secretion 
26 
controlled in AtT-20 cells and provide possible therapeutic implications in diseases such 
as Cushing's syndrome. 
27 
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